title: Efficacy and safety of intralesional corticosteroid application for hemangiomas.
abstract: OBJECTIVE
  There are different modalities for management of infantile hemangiomas (IHs). In this report, our aim is to evaluate whether intralesional corticosteroid treatment is associated with systemic side effects and whether this is an effective treatment modality for IH.
  
  
  METHODS
  Six children treated with intralesional corticosteroids for problematic hemangiomas were included in the study. Clinical characteristics, response to treatment, weight, height, blood pressure, morning serum cortisol, and adrenocorticotropic hormone levels were recorded.
  
  
  RESULTS
  Each child received intralesional triamcinolone at a dose of 2 mg/kg for 2-5 injections at monthly intervals. Subjects were followed for 1 year. All patients had adrenal suppression following the second or third triamcinolone injections. Five patients demonstrated partial response and one demonstrated no response.
  
  
  CONCLUSIONS
  Intralesional steroid injection may effectively induce the resolution of hemangiomas, but all the patients in our group had adrenal suppression after treatment. The use of intralesional steroid therapy is not a superior treatment option for hemangiomas. It also has side effects comparable to systemic steroids.
authors.forename: Suna
authors.initials: S
authors.lastname: Emir
authors.forename: Dilek
authors.initials: D
authors.lastname: Gürlek Gökçebay
authors.forename: Fatma
authors.initials: F
authors.lastname: Demirel
authors.forename: Bahattin
authors.initials: B
authors.lastname: Tunç
mesh_terms: D000293:Adolescent; D000309:Adrenal Insufficiency / Q000097:blood / Q000209:etiology; D000324:Adrenocorticotropic Hormone / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006391:Hemangioma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage / Q000009:adverse effects; D019043:Vascular Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D005938:Glucocorticoids; D014221:Triamcinolone; D000324:Adrenocorticotropic Hormone